aTyr Pharma (471A) Ownership - Who Owns aTyr Pharma?
aTyr Pharma (471A) Ownership Overview
- 2.55% Insiders
- 15.33% Mutual Funds
- 3.78% ETFs
- 78.34% Public Companies and Individual Investors
The ownership structure of aTyr Pharma (DE:471A) stock is a mix of institutional, retail, and individual investors. Approximately 19.11% of the company’s stock is owned by Institutional Investors, 2.55% is owned by Insiders, and 78.34% is owned by Public Companies and Individual Investors.
The ownership structure of aTyr Pharma (DE:471A) stock is a mix of institutional, retail, and individual investors. Approximately 19.11% of the company’s stock is owned by Institutional Investors, 2.55% is owned by Insiders, and 78.34% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| May 27, 2026 | Paul Schimmel | $49,000 | |
| Oct 08, 2025 | Paul Schimmel | $905,900 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Paul Schimmel | 2,201,056 | Insider | 89.76% | 570,074 |
| Fidelity Select Portfolios | 1,754,594 | Institution | 71.55% | 454,440 |
| Fidelity Concord Street Trust | 945,517 | Institution | 38.56% | 244,889 |
| Sanjay Shukla | 153,553 | Insider | 6.26% | 39,770 |
| Goldman Sachs Trust | 121,263 | Institution | 4.95% | 31,407 |
| Vanguard Valley Forge Funds | 56,767 | Institution | 2.31% | 14,703 |
| Timothy Coughlin | 56,000 | Insider | 2.28% | 14,504 |
| Vanguard Institutional Index Funds | 45,980 | Institution | 1.88% | 11,909 |
| Jill Marie Broadfoot | 37,296 | Insider | 1.52% | 9,660 |
| Nancy Denyes | 33,124 | Insider | 1.35% | 8,579 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Fidelity Select Portfolios | 1,754,594 | Institution | 71.55% | 454,440 |
| Fidelity Concord Street Trust | 945,517 | Institution | 38.56% | 244,889 |
| Goldman Sachs Trust | 121,263 | Institution | 4.95% | 31,407 |
| Vanguard Valley Forge Funds | 56,767 | Institution | 2.31% | 14,703 |
| Vanguard Institutional Index Funds | 45,980 | Institution | 1.88% | 11,909 |
| Fidelity Salem Street Trust | 19,962 | Institution | 0.81% | 5,170 |
| Bridge Builder Trust | 19,204 | Institution | 0.78% | 4,974 |
| John Hancock Variable Insurance Trust | 5,440 | Institution | 0.22% | 1,409 |
| Victory Portfolios Iii | 2,826 | Institution | 0.12% | 732 |
| Advisors' Inner Circle Iii | 507 | Institution | 0.02% | 131 |
FAQ
Who Owns aTyr Pharma (DE:471A)?
According to the latest TipRanks data, approximately 19.11% of the company's stock is held by institutional investors, 2.55% is held by insiders, and 78.34% is held by public companies and individual investors.
What percentage of aTyr Pharma (DE:471A) stock is held by institutional investors?
According to the latest TipRanks data, approximately 19.11% of aTyr Pharma (DE:471A) stock is held by institutional investors: 15.33% by mutual funds and 3.78% by ETFs.
What percentage of aTyr Pharma (DE:471A) stock is held by retail investors?
According to the latest TipRanks data, approximately 78.34% of aTyr Pharma (DE:471A) stock is held by public companies and individual investors.
Who owns the most shares of aTyr Pharma (DE:471A)?
Paul Schimmel owns the most shares of aTyr Pharma (DE:471A).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
